Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096707 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Threshold Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT00096707 is a Phase 1 study that has completed, run by Threshold Pharmaceuticals. The registered enrollment target is 50 participants.
The verdict
NCT00096707, a Phase 1 study, has completed, sponsored by Threshold Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the safety, tolerability, pharmacokinetics, and biologic effect (FDG PET, preliminary efficacy) of daily oral doses of 2DG with and without weekly docetaxel in subjects with advanced solid tumors.
Interventions
- DRUG 2-deoxy-D-glucose (2DG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2004-02 |
| Est. Completion | 2008-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00096707
The ClinicalTrials.gov registry entry for NCT00096707 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Threshold Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 2-deoxy-D-glucose (2DG) is the first listed.
NCT00096707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00096707 about?
NCT00096707 is a clinical study titled "Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors". The objectives of this study are to evaluate the safety, tolerability, pharmacokinetics, and biologic effect (FDG PET, preliminary efficacy) of daily oral doses of 2DG with and without weekly docetaxel in subjects with advanced solid tumors.
What is the current status of trial NCT00096707?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2004-02. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00096707?
The interventions under investigation include: 2-deoxy-D-glucose (2DG) (DRUG).
Who is sponsoring clinical trial NCT00096707?
This trial is sponsored by Threshold Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.